Health conditions and treatments in people with psoriasis treated at a Costa Rican hospital
Reviews medical records of people with psoriasis to describe their health and treatments.
Plain-language title generated from the registry record
Registry title: Psoriasis Comorbidities at Hospital Calderón Guardia
Key facts
- Where
- San José, Costa RicaSee the site
Where in Costa Rica
- Caja Costarricense del Seguro SocialSan José, Costa RicaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Caja Costarricense de Seguro Social
- Trial code
- NCT07448337
- Record updated
- 8 April 2026
- Original description
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:Read full original descriptionShow less
Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:
What are the demographic and clinical characteristics and severity profiles of psoriasis patients?
What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?
Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.
Inclusion: Patients evaluated in outpatient clinics during the period 2024-2025; Patients receiving systemic therapy and/or phototherapy; Patients aged 12 years or older, of any sex; Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis; At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period; Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.
Exclusion: Patients managed exclusively with topical therapies; Cutaneous conditions not compatible with psoriasis; Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile; Duplicate or inconsistent records, preventing accurate patient classification.